2022
Consideration of sex and gender differences in addiction medication response
McKee SA, McRae-Clark AL. Consideration of sex and gender differences in addiction medication response. Biology Of Sex Differences 2022, 13: 34. PMID: 35761351, PMCID: PMC9235243, DOI: 10.1186/s13293-022-00441-3.Peer-Reviewed Original ResearchConceptsSubstance use disordersMedication developmentUse disordersMedication development researchPreventable health conditionsClinical care guidelinesPublic health burdenNational InstituteSex-stratified dataGender differencesCurrent narrative reviewDrugs of abuseMedication trialsSignificant morbidityCare guidelinesMedication responseHealth burdenAbused substancesAlcohol abuseConsideration of sexNarrative reviewIncorporation of sexDrug abuseHealth conditionsSubstance use
2020
A Critical Review of Alcohol Administration Guidelines in Laboratory Medication Screening Research: Is It Time to Include Treatment Seekers?
Roberts W, Verplaetse TL, Ramchandani VA, McKee SA. A Critical Review of Alcohol Administration Guidelines in Laboratory Medication Screening Research: Is It Time to Include Treatment Seekers? Alcohol Clinical And Experimental Research 2020, 45: 15-24. PMID: 33190310, PMCID: PMC7855436, DOI: 10.1111/acer.14514.Peer-Reviewed Original ResearchConceptsHuman laboratory studiesTreatment seekersNontreatment seekersExpensive clinical trialsPatient populationAlcohol administrationClinical trialsMedication effectsClinical conditionsMedication developmentMedicationsHeavy drinkersMedication experimentsLaboratory screeningClinical realityAdministration guidelinesScreening researchDevelopment pipelineLaboratory studiesRiskGuidelinesParticipantsPharmacotherapyPopulationEthical guidelines
2018
Sex differences in the nicotinic acetylcholine and dopamine receptor systems underlying tobacco smoking addiction
Verplaetse T, Morris ED, McKee SA, Cosgrove KP. Sex differences in the nicotinic acetylcholine and dopamine receptor systems underlying tobacco smoking addiction. Current Opinion In Behavioral Sciences 2018, 23: 196-202. PMID: 31341936, PMCID: PMC6656369, DOI: 10.1016/j.cobeha.2018.04.004.Peer-Reviewed Original ResearchSmoking addictionNicotinic acetylcholine receptor systemReceptor systemNon-nicotine factorsRecent imaging literatureSex differencesNicotine replacement therapyDopamine receptor systemAcetylcholine receptor systemNicotine-motivated behaviorsFuture medication developmentNicotine-related reinforcementTobacco smokingImaging findingsNicotine administrationReplacement therapyDopaminergic systemNeurochemical mechanismsNicotinic acetylcholineDopamine systemMedication developmentLines of evidenceSmokingImaging literatureWomen
2015
Targeting the Noradrenergic System for Gender-Sensitive Medication Development for Tobacco Dependence
Verplaetse TL, Weinberger AH, Smith PH, Cosgrove KP, Mineur YS, Picciotto MR, Mazure CM, McKee SA. Targeting the Noradrenergic System for Gender-Sensitive Medication Development for Tobacco Dependence. Nicotine & Tobacco Research 2015, 17: 486-495. PMID: 25762760, PMCID: PMC4432402, DOI: 10.1093/ntr/ntu280.Peer-Reviewed Original ResearchConceptsSmoking cessationNoradrenergic systemClinical evidenceTobacco dependenceNoradrenergic activityMedication developmentPoor smoking cessation outcomesCause of morbiditySmoking cessation outcomesStress reactivitySex-specific mechanismsLower quit ratesNicotine-related reinforcementCurrent medicationsMedication effectivenessNicotine reinforcementCessation outcomesNoradrenergic agentsQuit ratesTreatment strategiesTobacco useNoradrenergic compoundsSmoking outcomesTreatment developmentWomen
2012
Developing and Validating a Human Laboratory Model to Screen Medications for Smoking Cessation
McKee SA, Weinberger AH, Shi J, Tetrault J, Coppola S. Developing and Validating a Human Laboratory Model to Screen Medications for Smoking Cessation. Nicotine & Tobacco Research 2012, 14: 1362-1371. PMID: 22492085, PMCID: PMC3482010, DOI: 10.1093/ntr/nts090.Peer-Reviewed Original ResearchConceptsSubsequent ad libitum smokingSmoking cessation medicationsAd libitum smokingCessation medicationsNicotine deprivationSmoking cessationNovel smoking cessation medicationsRatings of cravingSmoking lapse behaviorHuman laboratory modelSecondary outcomesClinical efficacyClinical findingsFirst cigaretteMedication effectsSmokingMedication developmentCigarette effectsMedicationsLapse behaviorSmoking lapseTranslational toolScreen medicationsMonetary reinforcementTranslational work
2008
Developing human laboratory models of smoking lapse behavior for medication screening
McKee SA. Developing human laboratory models of smoking lapse behavior for medication screening. Addiction Biology 2008, 14: 99-107. PMID: 18855800, PMCID: PMC2732001, DOI: 10.1111/j.1369-1600.2008.00135.x.Peer-Reviewed Original ResearchConceptsMedication screeningHuman laboratory modelSmoking behaviorMedication developmentSubsequent ad libitum smokingAd libitum smokingDrug Administration approvalSelf-administration sessionsMedication signalsCessation medicationsLapse behaviorAdministration approvalFirst cigaretteAbstinence outcomesQuit attemptsSmoking relapseUS FoodSmokingSmokersRelapseImportant targetTranslational workCigarettesScreeningMechanistic evaluation